A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

StatusCompleted
PhasePhase 3
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 5 entries Show 5 more changesShow less
    • Trial completed
    • Primary and study completion dates changed from estimate of Aug 31, 2026 to Aug 25, 2026
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 5 of 5 sites
    • Eligibility criteria expanded, about 2 words
  2. Recruitment opened
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 5 of 5 sites
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Pfizer
438 trials monitored
See 32 trials at risk
The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways. The study is seeking participants who are: * 18 to 59 years of age * adults with health condition(s) that can put them at an increased risk of severe RSV disease It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.
Trial Details
NCT Number NCT07543380
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Respiratory Syncytial Virus (RSV)
Enrollment 130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov